Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Olanzapine 5 mg vs Zyprexa in Healthy Subjects
NCT05123976Phase 1Completed
- Sponsor
- Farmak
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olanzapine in schizophrenia and bipolar disorder (BD) (2 arms), sponsored by Farmak. Primary endpoints: Area Under the Curve from time 0 to 72 hours and Maximum Plasma Concentration. Started Oct 2020; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT05123976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123976.